Ablad B, Carlsson E, Ek L, Johnsson G
Scott Med J. 1977 Jan;22(1):52-63. doi: 10.1177/003693307702200115.
The therapeutic effect of beta adrenoceptor blockers in angina pectoris can be ascribed to an inhibition of beta1 receptor mediated stimulation of heart rate and myocardial contractility, resulting in an improved oxygen supply-demand balance in the myocardium. When given in equipotent beta1 blocking doses, the nonselective blocker propranolol and the beta1 selective blocker metoprolol differ markedly as regards inhibition of adrenaline induced beta2 mediated vasodilatation. Only propranolol will inhibit this effect. After propranolol, adrenaline therefore elicits a haemodynamic effect pattern characterized by high peripheral vascular resistance, high arterial blood pressure, low cardiac output and increased cardiac size. In view of these findings it is suggested that a beta1 selective blocker may be a more efficient antianginal agent than a nonselective blocker in those patients in which the anginal attack is associated with a significant release of adrenaline. The clinical relevance of this hypothesis has not been tested.
β肾上腺素受体阻滞剂治疗心绞痛的效果可归因于抑制β1受体介导的心率和心肌收缩力刺激,从而改善心肌的氧供需平衡。当给予等效的β1阻断剂量时,非选择性阻滞剂普萘洛尔和β1选择性阻滞剂美托洛尔在抑制肾上腺素诱导的β2介导的血管舒张方面有显著差异。只有普萘洛尔会抑制这种作用。因此,使用普萘洛尔后,肾上腺素会引发一种血流动力学效应模式,其特征为外周血管阻力高、动脉血压高、心输出量低和心脏大小增加。鉴于这些发现,有人提出,在心绞痛发作与大量肾上腺素释放相关的患者中,β1选择性阻滞剂可能比非选择性阻滞剂更有效地抗心绞痛。这一假设的临床相关性尚未得到验证。